Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kairos Pharma (KAPA) Net Income (2024 - 2025)

Kairos Pharma's Net Income history spans 2 years, with the latest figure at -$1.4 million for Q2 2025.

  • For Q2 2025, Net Income fell 507.69% year-over-year to -$1.4 million; the TTM value through Dec 2025 reached -$4.1 million, down 42.27%, while the annual FY2025 figure was -$5.4 million, 129.06% down from the prior year.
  • Net Income reached -$1.4 million in Q2 2025 per KAPA's latest filing, down from -$1.3 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$234000.0 in Q2 2024 to a low of -$1.4 million in Q4 2024.